Phase II Study of Oxaliplatin, Xeloda, and cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Capecitabine (Primary) ; Cetuximab (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Pharmacogenomic; Therapeutic Use
- 14 May 2019 Planned End Date changed from 28 Jun 2019 to 28 Dec 2019.
- 28 Mar 2018 Planned End Date changed from 28 Jun 2018 to 28 Jun 2019.
- 28 Mar 2018 Planned primary completion date changed from 28 Dec 2017 to 28 Dec 2018.